Page last updated: 2024-10-27

gabexate and Multiple Sclerosis

gabexate has been researched along with Multiple Sclerosis in 1 studies

Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Inuzuka, T1
Sato, S1
Baba, H1
Miyatake, T1

Other Studies

1 other study available for gabexate and Multiple Sclerosis

ArticleYear
Neutral protease in cerebrospinal fluid from patients with multiple sclerosis and other neurological diseases.
    Acta neurologica Scandinavica, 1987, Volume: 76, Issue:1

    Topics: Amyotrophic Lateral Sclerosis; Endopeptidases; Esters; Follow-Up Studies; Gabexate; Guanidines; Huma

1987